Biochemical Basis of Asthma Therapy*

Current therapy for asthma is highly effective. β2-Adrenergic receptor (β2AR) agonists are the most effective bronchodilators and relax airway smooth muscle cells through increased cAMP concentrations and directly opening large conductance Ca2+ channels. β2AR may also activate alternative signaling pathways that may have detrimental effects in asthma. Glucocorticoids are the most effective anti-inflammatory treatments and switch off multiple activated inflammatory genes through recruitment of histone deacetylase-2, activating anti-inflammatory genes, and through increasing mRNA stability of inflammatory genes. There are beneficial molecular interactions between β2AR and glucocorticoid-activated pathways. Understanding these signaling pathways may lead to even more effective therapies in the future.

[1]  E. R. Sutherland,et al.  Tiotropium bromide step-up therapy for adults with uncontrolled asthma. , 2010, The New England journal of medicine.

[2]  J. V. van Noord,et al.  QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease , 2010, Thorax.

[3]  James G. Bollinger,et al.  Eosinophil Cysteinyl Leukotriene Synthesis Mediated by Exogenous Secreted Phospholipase A2 Group X* , 2010, The Journal of Biological Chemistry.

[4]  I. Adcock,et al.  Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. , 2010, American journal of respiratory and critical care medicine.

[5]  P. Barnes,et al.  Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. , 2010, The Journal of allergy and clinical immunology.

[6]  D. Schwartz,et al.  Both hematopoietic-derived and non-hematopoietic-derived {beta}-arrestin-2 regulates murine allergic airway disease. , 2010, American journal of respiratory cell and molecular biology.

[7]  A. Hatzelmann,et al.  The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. , 2010, Pulmonary pharmacology & therapeutics.

[8]  P. Barnes.  New therapies for asthma: is there any progress? , 2010, Trends in pharmacological sciences.

[9]  M. Newcomer,et al.  Location, Location, Location: Compartmentalization of Early Events in Leukotriene Biosynthesis* , 2010, The Journal of Biological Chemistry.

[10]  R. Leigh,et al.  Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung diseases. , 2010, Pharmacology & therapeutics.

[11]  G. Chrousos,et al.  The human glucocorticoid receptor: Molecular basis of biologic function , 2010, Steroids.

[12]  E. Bateman,et al.  Alternative mechanisms for tiotropium. , 2009, Pulmonary pharmacology & therapeutics.

[13]  I. Adcock,et al.  Hypoxia-inducible Factor 1α Induces Corticosteroid-insensitive Inflammation via Reduction of Histone Deacetylase-2 Transcription* , 2009, The Journal of Biological Chemistry.

[14]  M. Cazzola,et al.  Emerging inhaled bronchodilators: an update , 2009, European Respiratory Journal.

[15]  Patrick W Serruys,et al.  Phospholipase A2 inhibitors , 2009, Current opinion in lipidology.

[16]  Kazuhiro Ito,et al.  Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2. , 2009, Biochemical and biophysical research communications.

[17]  I. Adcock,et al.  Glucocorticoid resistance in inflammatory diseases , 2009, The Lancet.

[18]  I. Adcock,et al.  Suppression of GATA-3 Nuclear Import and Phosphorylation: A Novel Mechanism of Corticosteroid Action in Allergic Disease , 2009, PLoS medicine.

[19]  Christopher S. Stevenson,et al.  Inhibition of PI3Kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice. , 2009, American journal of respiratory and critical care medicine.

[20]  L. Bohn,et al.  Physiological and pharmacological implications of beta-arrestin regulation. , 2009, Pharmacology & therapeutics.

[21]  B. J. Knoll,et al.  β2-Adrenoceptor signaling is required for the development of an asthma phenotype in a murine model , 2009, Proceedings of the National Academy of Sciences.

[22]  P. Barnes,et al.  Role of HDAC2 in the pathophysiology of COPD. , 2009, Annual review of physiology.

[23]  Qutayba Hamid,et al.  Immunobiology of asthma. , 2009, Annual review of physiology.

[24]  P. Barnes,et al.  The cytokine network in asthma and chronic obstructive pulmonary disease. , 2008, The Journal of clinical investigation.

[25]  Ming Xu,et al.  A Novel Protein Kinase A-independent, β-Arrestin-1-dependent Signaling Pathway for p38 Mitogen-activated Protein Kinase Activation by β2-Adrenergic Receptors* , 2008, Journal of Biological Chemistry.

[26]  C. Wilson.  Adenosine receptors and asthma in humans , 2008, British journal of pharmacology.

[27]  C. Kirkpatrick,et al.  Acetylcholine beyond neurons: the non‐neuronal cholinergic system in humans , 2008, British journal of pharmacology.

[28]  T. Wieland,et al.  M2 Muscarinic Receptors Induce Airway Smooth Muscle Activation via a Dual, Gβγ-mediated Inhibition of Large Conductance Ca2+-activated K+ Channel Activity* , 2008, Journal of Biological Chemistry.

[29]  W. Kummer,et al.  The epithelial cholinergic system of the airways , 2008, Histochemistry and Cell Biology.

[30]  J. Sondek,et al.  Activation of human phospholipase C-eta2 by Gbetagamma. , 2008, Biochemistry.

[31]  J. Stamatoyannopoulos,et al.  Interaction of the Glucocorticoid Receptor with the Chromatin Landscape , 2008, Molecular cell.

[32]  E. Bleecker,et al.  Clinical consequences of ADRbeta2 polymorphisms. , 2008, Pharmacogenomics.

[33]  P. Barnes.  Immunology of asthma and chronic obstructive pulmonary disease , 2008, Nature Reviews Immunology.

[34]  M. Flashner,et al.  The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. , 2008, Pulmonary pharmacology & therapeutics.

[35]  P. J. Barnes,et al.  Global strategy for asthma management and prevention: GINA executive summary , 2008, European Respiratory Journal.

[36]  D. Postma,et al.  Effect of ADRB2 polymorphisms on response to longacting β2-agonist therapy: a pharmacogenetic analysis of two randomised studies , 2007, The Lancet.

[37]  W. Henderson,et al.  Mechanisms of disease: Leukotrienes , 2007 .

[38]  A. Halayko,et al.  Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison , 2007, European Respiratory Journal.

[39]  K. Asadullah,et al.  Selective glucocorticoid receptor agonists (SEGRAs): Novel ligands with an improved therapeutic index , 2007, Molecular and Cellular Endocrinology.

[40]  J. Violin,et al.  β-Arrestin-biased ligands at seven-transmembrane receptors , 2007 .

[41]  J. Mullol,et al.  Alpha and beta glucocorticoid receptors: Relevance in airway diseases , 2007, Current Allergy and Asthma Reports.

[42]  R. Lefkowitz,et al.  β-Arrestins and Cell Signaling , 2007 .

[43]  Ian M. Adcock,et al.  Regulation of Th2 Cytokine Genes by p38 MAPK-Mediated Phosphorylation of GATA-31 , 2007, The Journal of Immunology.

[44]  P. Gibson,et al.  Differential effects of maintenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. , 2007, The Journal of allergy and clinical immunology.

[45]  J. Collins,et al.  Human Glucocorticoid Receptor β Binds RU-486 and Is TranscriptionallyActive , 2007, Molecular and Cellular Biology.

[46]  P. Dorinsky,et al.  Safety of Long-Acting -Agonists , 2006, Annals of Internal Medicine.

[47]  M. Harbeck,et al.  Cell physiology of cAMP sensor Epac , 2006, The Journal of physiology.

[48]  J. Cidlowski,et al.  Glucocorticoids Regulate Tristetraprolin Synthesis and Posttranscriptionally Regulate Tumor Necrosis Factor Alpha Inflammatory Signaling , 2006, Molecular and Cellular Biology.

[49]  I. Adcock,et al.  Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. , 2006, American journal of respiratory and critical care medicine.

[50]  G. Lukács,et al.  Importin 13 regulates nuclear import of the glucocorticoid receptor in airway epithelial cells. , 2006, American journal of respiratory cell and molecular biology.

[51]  P. Barnes.  How corticosteroids control inflammation: Quintiles Prize Lecture 2005 , 2006, British journal of pharmacology.

[52]  J. Cidlowski,et al.  The Physiology of Human Glucocorticoid Receptor β (hGRβ) and Glucocorticoid Resistance , 2006 .

[53]  P. J. Barnes,et al.  Corticosteroid effects on cell signalling , 2006, European Respiratory Journal.

[54]  I. Adcock,et al.  Histone deacetylase 2–mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression , 2006, The Journal of experimental medicine.

[55]  A. Fryer,et al.  Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction. , 2005, The Journal of clinical investigation.

[56]  J. Cidlowski,et al.  Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. , 2005, The New England journal of medicine.

[57]  Malcolm Johnson,et al.  Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. , 2005, American journal of respiratory and critical care medicine.

[58]  G. Cruse,et al.  β2‐Adrenoceptor regulation of the K+ channel iKCa1 in human mast cells , 2005 .

[59]  E. Israel,et al.  Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial , 2004, The Lancet.

[60]  I. Adcock,et al.  Theophylline Restores Histone Deacetylase Activity and Steroid Responses in COPD Macrophages , 2004, The Journal of experimental medicine.

[61]  D. Goldfarb,et al.  Importin α: A multipurpose nuclear-transport receptor , 2004 .

[62]  T. Heinzel,et al.  Negative glucocorticoid receptor response elements and their role in glucocorticoid action. , 2004, Current pharmaceutical design.

[63]  I. Adcock,et al.  Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients. , 2004, The Journal of allergy and clinical immunology.

[64]  M. Garabedian,et al.  Modulation of Glucocorticoid Receptor Function via Phosphorylation , 2004, Annals of the New York Academy of Sciences.

[65]  P. Barnes,et al.  Glucocorticoid inhibition of granulocyte macrophage-colony-stimulating factor from T cells is independent of control by nuclear factor-kappaB and conserved lymphokine element 0. , 2004, American journal of respiratory cell and molecular biology.

[66]  I. Adcock,et al.  How Do Corticosteroids Work in Asthma? , 2003, Annals of Internal Medicine.

[67]  A. Clark.  MAP kinase phosphatase 1: a novel mediator of biological effects of glucocorticoids? , 2003, The Journal of endocrinology.

[68]  P. Barnes.  Theophylline: new perspectives for an old drug. , 2003, American journal of respiratory and critical care medicine.

[69]  M. Roth,et al.  Interaction between glucocorticoids and β2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling , 2002, The Lancet.

[70]  I. Adcock,et al.  A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[71]  I. Adcock,et al.  p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. , 2002, The Journal of allergy and clinical immunology.

[72]  P. Barnes,et al.  Increased expression of G protein-coupled receptor kinases in cystic fibrosis lung. , 2002, European journal of pharmacology.

[73]  J. Mak,et al.  Glucocorticoids reverse IL‐1β‐induced impairment of β‐adrenoceptor‐mediated relaxation and up‐regulation of G‐protein‐coupled receptor kinases , 2002 .

[74]  P. Barnes,et al.  Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids , 2002, European Respiratory Journal.

[75]  S. Hasegawa,et al.  Theophylline inhibits NF-κB activation and IκBα degradation in human pulmonary epithelial cells , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.

[76]  T. Kohout,et al.  Regulation of Receptor Fate by Ubiquitination of Activated β2-Adrenergic Receptor and β-Arrestin , 2001, Science.

[77]  P. Howarth,et al.  The effect of long-acting beta2-agonists on airway inflammation in asthmatic patients. , 2000, Respiratory medicine.

[78]  I. Adcock,et al.  Glucocorticoid Receptor Recruitment of Histone Deacetylase 2 Inhibits Interleukin-1β-Induced Histone H4 Acetylation on Lysines 8 and 12 , 2000, Molecular and Cellular Biology.

[79]  Y. H. Kim,et al.  The downregulation of Bcl-2 expression is necessary for theophylline-induced apoptosis of eosinophil. , 2000, Cellular immunology.

[80]  K. Shinozaki,et al.  Theophylline induces neutrophil apoptosis through adenosine A2A receptor antagonism , 2000, Journal of leukocyte biology.

[81]  S. Liggett,et al.  Heterogeneity in β-Adrenergic Receptor Kinase Expression in the Lung Accounts for Cell-specific Desensitization of the β2-Adrenergic Receptor* , 1997, The Journal of Biological Chemistry.

[82]  T. Troost,et al.  Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa. , 1997, American journal of respiratory and critical care medicine.

[83]  P. Barnes,et al.  Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo. , 1995, The Journal of clinical investigation.

[84]  J. Lammers,et al.  A muscarinic agonist inhibits reflex bronchoconstriction in normal but not in asthmatic subjects. , 1989, Journal of applied physiology.

[85]  G. Cruse,et al.  Counterregulation of beta(2)-adrenoceptor function in human mast cells by stem cell factor. , 2010, The Journal of allergy and clinical immunology.

[86]  R. Panettieri,et al.  Inhibition of human airway smooth muscle cell proliferation by beta 2-adrenergic receptors and cAMP is PKA independent: evidence for EPAC involvement. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[87]  P. Barnes,et al.  Sputum indoleamine-2, 3-dioxygenase activity is increased in asthmatic airways by using inhaled corticosteroids. , 2008, The Journal of allergy and clinical immunology.